Sign In
Buy CCXI
$13.86
-0.140 (-1.00%)
At Close: Jul 31, 2026
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ChemoCentryx, Inc. - CCXI
10:26pm, Wednesday, 05'th May 2021
NEW YORK, May 5, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ChemoCentryx, Inc. ("ChemoCentryx" or the "Company") (NASDAQ: CCXI). Such investors are ad
CCXI INVESTORS ACT NOW: Contact HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, to Recover Losses Due to Alleged Securities Fraud
07:29pm, Wednesday, 05'th May 2021
San Francisco, California--(Newsfile Corp. - May 5, 2021) - Hagens Berman urges ChemoCentryx, Inc. (NASDAQ: CCXI) investors with significant losses to submit your losses now. A securities fraud class
Ademi LLP Investigates Claims of Securities Fraud against ChemoCentryx Inc.
01:16pm, Wednesday, 05'th May 2021
MILWAUKEE, May 5, 2021 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against ChemoCentryx (NASDAQ: CCXI). The investigation results from inaccurate statements ChemoCentr
SAN FRANCISCO, May 5, 2021 /PRNewswire/ -- Hagens Berman urges ChemoCentryx, Inc. (NASDAQ: CCXI) investors with significant losses to submit your losses now. The firm is investigating possible secu
LOS ANGELES--(BUSINESS WIRE)---- $CCXI #CCXI--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ChemoCentryx, Inc.
Why ChemoCentryx Stock Crashed Today
04:06pm, Tuesday, 04'th May 2021
The FDA's briefing documents for an advisory committee don't appear to bode well for avacopan's chances of approval.
Why Cocrystal Pharma, Chemocentryx, Neuronetics And BioLineRx Are Moving Today
01:45pm, Tuesday, 04'th May 2021
Cocrystal Pharma, Inc. (NASDAQ: COCP), ChemoCentryx, Inc. (NASDAQ: CCXI), Neuronetics, Inc. (NASDAQ: STIM) and BioLineRx Ltd. (NASDAQ: BLRX) are among the biggest health care movers Tuesday.
Boston, Massachusetts--(Newsfile Corp. - May 4, 2021) - Block & Leviton LLP announces that the firm is investigating whether ChemoCentryx, Inc. (NASDAQ: CCXI) committed securities fraud. Investors who
ChemoCentryx Stock Plunges As FDA Briefing Document Casts Doubt On Vasculitis Candidate Avacopan's Data
01:19pm, Tuesday, 04'th May 2021
ChemoCentryx Inc (NASDAQ: CCXI) shares plunged after an FDA briefing document indicates the agency has “several areas of concerns” with its vasculitis candidate, avacopan. The FDA document rai
CCXI Stock: From $48.82 To $24.60 (49.61% Decrease) Intraday Explanation
12:31pm, Tuesday, 04'th May 2021
The stock price of ChemoCentryx Inc (NASDAQ: CCXI) fell from $48.82 to $24.60 (down 49.61%) during intraday trading. This is why it happened.
ChemoCentryx's stock dives after critique from the FDA about experimental treatment for rare autoimmune disease
12:03pm, Tuesday, 04'th May 2021
Shares of ChemoCentryx Inc. plunged 44.8% in trading on Tuesday after the Food and Drug Administration questioned the rationale behind some of the clinical data for avacopan, an experimental treatment
ChemoCentryx, Inc.'s (CCXI) CEO Dr. Thomas Schall on Q1 2021 Results - Earnings Call Transcript
11:52pm, Thursday, 29'th Apr 2021
ChemoCentryx, Inc.'s (CCXI) CEO Dr. Thomas Schall on Q1 2021 Results - Earnings Call Transcript
ChemoCentryx (CCXI) Reports Q1 Loss, Tops Revenue Estimates
06:47pm, Thursday, 29'th Apr 2021
ChemoCentryx (CCXI) delivered earnings and revenue surprises of -7.50% and 19.16%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
ChemoCentryx Reports First Quarter 2021 Financial Results and Recent Highlights
04:05pm, Thursday, 29'th Apr 2021
-- Applications for regulatory approval of avacopan in ANCA-associated vasculitis under review in the United States, Europe and Japan; PDUFA goal date of July 7, 2021, with Advisory Committee schedule
-- CCX559 enhanced primary human T cell activity in vitro and demonstrated anti-tumor efficacy in two murine tumor models -- -- Company plans to advance CCX559 into clinical development in the first h
